Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss
Biomolecules · 13.03.2025 · 15 (3) · 408
DOI: 10.3390/biom15030408 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 13.03.2025. Verfasst von Allison B Reiss und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, NYU Grossman Long Island School of Medicine, Mineola, NY 11501, USA. Hauptthemen laut MEDLINE: Weight Loss, Glucagon-Like Peptide 1, Obesity. Die Arbeit wurde bisher 65-mal zitiert (Crossref) und nennt 305 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Worldwide, nearly 40% of adults are overweight and 13% are obese. Health consequences of excess weight include cardiovascular diseases, type 2 diabetes, dyslipidemia, and increased mortality. Treating obesity is challenging and calorie restriction often leads to rebound weight gain. Treatments such as bariatric surgery create hesitancy among patients due to their invasiveness. GLP-1 medications have revolutionized weight loss and can reduce body weight in obese patients by between 15% and 25% on average after about 1 year. Their mode of action is to mimic the endogenous GLP-1, an intestinal hormone that regulates glucose metabolism and satiety. However, GLP-1 drugs carry known risks and, since their use for weight loss is recent, may carry unforeseen risks as well. They carry a boxed warning for people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Gastrointestinal adverse events (nausea, vomiting, diarrhea) are fairly common while pancreatitis and intestinal obstruction are rarer. There may be a loss of lean body mass as well as premature facial aging. A significant disadvantage of using these medications is the high rate of weight regain when they are discontinued. Achieving success with pharmacologic treatment and then weaning to avoid future negative effects would be ideal.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, NYU Grossman Long Island School of Medicine, Mineola, NY 11501, USA.
- Department of Foundations of Medicine, NYU Grossman Long Island School of Medicine, Mineola, NY 11501, USA.
ORCID-Profile: Allison B Reiss, Shelly Gulkarov, Stanislaw P Klek, Ankita Srivastava
Zitieren
APA
Reiss, A. B., Gulkarov, S., Lau, R., Klek, S. P., Srivastava, A., Renna, H. A., & De Leon, J. (2025). Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss. Biomolecules, 15(3), 408. https://doi.org/10.3390/biom15030408
Vancouver
Reiss AB, Gulkarov S, Lau R, Klek SP, Srivastava A, Renna HA, et al. Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss. Biomolecules. 2025;15(3):408. doi:10.3390/biom15030408
BibTeX
@article{Reiss2025,
author = {Reiss, Allison B and Gulkarov, Shelly and Lau, Raymond and Klek, Stanislaw P and Srivastava, Ankita and Renna, Heather A and De Leon, Joshua},
title = {Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss},
journal = {Biomolecules},
year = {2025},
volume = {15},
number = {3},
pages = {408},
doi = {10.3390/biom15030408}
}
EUVIMED